DE602004010845D1 - Aroylfurane und aroylthiophene, die sich für die behandlung von krebs eignen - Google Patents

Aroylfurane und aroylthiophene, die sich für die behandlung von krebs eignen

Info

Publication number
DE602004010845D1
DE602004010845D1 DE602004010845T DE602004010845T DE602004010845D1 DE 602004010845 D1 DE602004010845 D1 DE 602004010845D1 DE 602004010845 T DE602004010845 T DE 602004010845T DE 602004010845 T DE602004010845 T DE 602004010845T DE 602004010845 D1 DE602004010845 D1 DE 602004010845D1
Authority
DE
Germany
Prior art keywords
compounds
formula
treatment
aroylthiophene
aroylfurane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004010845T
Other languages
English (en)
Other versions
DE602004010845T2 (de
Inventor
Martin Eberle
Felix Bachmann
Alessandro Strebel
Subho Roy
Goutam Saha
Subir Kumar Sadhukhan
Rohit Saxena
Sudhir Srivastava
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Basilea Pharmaceutica AG
Original Assignee
Basilea Pharmaceutica AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basilea Pharmaceutica AG filed Critical Basilea Pharmaceutica AG
Publication of DE602004010845D1 publication Critical patent/DE602004010845D1/de
Application granted granted Critical
Publication of DE602004010845T2 publication Critical patent/DE602004010845T2/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DE602004010845T 2003-12-22 2004-12-21 Aroylfurane und aroylthiophene, die sich für die behandlung von krebs eignen Active DE602004010845T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP03405912 2003-12-22
EP03405912 2003-12-22
EP03405911 2003-12-22
EP03405911 2003-12-22
EP04405517 2004-08-19
EP04405517 2004-08-19
PCT/EP2004/053622 WO2005061476A2 (en) 2003-12-22 2004-12-21 Aroylfuranes and aroylthiophenes

Publications (2)

Publication Number Publication Date
DE602004010845D1 true DE602004010845D1 (de) 2008-01-31
DE602004010845T2 DE602004010845T2 (de) 2008-12-04

Family

ID=34714028

Family Applications (2)

Application Number Title Priority Date Filing Date
DE602004025302T Active DE602004025302D1 (de) 2003-12-22 2004-12-21 Aryloxy- und Arylthioxyacetophenon-Verbindungen zur Behandlung von Krebs
DE602004010845T Active DE602004010845T2 (de) 2003-12-22 2004-12-21 Aroylfurane und aroylthiophene, die sich für die behandlung von krebs eignen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE602004025302T Active DE602004025302D1 (de) 2003-12-22 2004-12-21 Aryloxy- und Arylthioxyacetophenon-Verbindungen zur Behandlung von Krebs

Country Status (9)

Country Link
US (1) US8486996B2 (de)
EP (2) EP1697336B1 (de)
JP (1) JP4805166B2 (de)
CN (1) CN101061101B (de)
AT (2) ATE455765T1 (de)
CA (1) CA2545821C (de)
DE (2) DE602004025302D1 (de)
ES (2) ES2298853T3 (de)
WO (1) WO2005061476A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007019344A1 (en) 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Imidazo [2,1-b] thiayole derivatives as sirtuin modulating compounds
US7723330B2 (en) 2006-03-07 2010-05-25 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use
MX2009001878A (es) * 2006-08-21 2009-03-03 Genentech Inc Compuestos de aza-benzofuranilo y metodos de uso.
US7893085B2 (en) 2006-08-21 2011-02-22 Genentech, Inc Aza-benzothiophenyl compounds and methods of use
RU2448111C2 (ru) * 2006-08-21 2012-04-20 Дженентек, Инк. Соединения азабензофуранила и способ их применения
ZA200900896B (en) * 2006-08-21 2010-06-30 Genentech Inc Aza-benzofuranyl compounds and methods of use
JP2010518014A (ja) * 2007-01-31 2010-05-27 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用な２−アミノピリジン誘導体
KR20100093552A (ko) 2007-11-02 2010-08-25 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 ｃ-세타로서의 [1ｈ-피라졸로[3,4-ｂ]피리딘-4-일]-페닐 또는 -피리딘-2-일 유도체
MX2010014559A (es) 2008-07-01 2011-03-04 Genentech Inc Heterociclos bicíclicos sustituidos y metodos de uso.
MX2010014565A (es) 2008-07-01 2011-03-04 Genentech Inc Isoindolona y metodos de uso.
WO2010011768A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
NZ590784A (en) 2008-07-23 2012-12-21 Vertex Pharma Pyrazolopyridine kinase inhibitors
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
MX2011001319A (es) * 2008-08-06 2011-04-05 Vertex Pharma Inhibidores de aminopiridina cinasa.
JP5627675B2 (ja) 2009-05-06 2014-11-19 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ピラゾロピリジン
AU2011209649A1 (en) 2010-01-27 2012-08-09 Vertex Pharmaceuticals Incorporated Pyrazolopyrazine kinase inhibitors
CA2787315A1 (en) 2010-01-27 2011-08-04 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
AU2011209651A1 (en) 2010-01-27 2012-08-09 Vertex Pharmaceuticals Incorporated Pyrazolopyrimidine kinase inhibitors
SG11202102332QA (en) 2018-09-22 2021-04-29 Torrent Pharmaceuticals Ltd Methods of producing pyrazole compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2350109A (en) * 1999-05-17 2000-11-22 Bayer Ag Pharmaceutically active benzofuranyl sulfonates
AU6315300A (en) 1999-07-26 2001-02-13 Shionogi & Co., Ltd. Benzene derivatives and immunopotentiating compositions or drug-sensitivity restoring agents containing the same
GB9920872D0 (en) * 1999-09-04 1999-11-10 Glaxo Group Ltd Benzophenones as inhibitors of reverse transcriptase
DE19947154A1 (de) * 1999-10-01 2001-10-04 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
CA2440842A1 (en) * 2001-04-16 2002-10-24 Eisai Co., Ltd. Novel 1h-indazole compounds
US7144885B2 (en) * 2002-02-22 2006-12-05 Bayer Pharmaceuticals Corporation Fused tricyclic heterocycles useful for treating hyper-proliferative disorders
NZ534255A (en) * 2002-02-22 2007-06-29 Bayer Pharmaceuticals Corp Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders
EP1534715B1 (de) * 2002-07-11 2007-08-15 Bayer Pharmaceuticals Corporation Furopyridin- und furopyrimidinderivate zur behandlung von hyperproliferativen erkrankungen

Also Published As

Publication number Publication date
EP1894917B1 (de) 2010-01-20
EP1697336B1 (de) 2007-12-19
US8486996B2 (en) 2013-07-16
EP1697336A2 (de) 2006-09-06
US20060205739A1 (en) 2006-09-14
ATE381554T1 (de) 2008-01-15
CA2545821A1 (en) 2005-07-07
CN101061101B (zh) 2011-09-07
DE602004010845T2 (de) 2008-12-04
WO2005061476A2 (en) 2005-07-07
WO2005061476A3 (en) 2006-01-26
EP1894917A1 (de) 2008-03-05
JP4805166B2 (ja) 2011-11-02
CN101061101A (zh) 2007-10-24
DE602004025302D1 (de) 2010-03-11
ATE455765T1 (de) 2010-02-15
JP2007517787A (ja) 2007-07-05
CA2545821C (en) 2010-09-21
ES2338060T3 (es) 2010-05-03
ES2298853T3 (es) 2008-05-16

Similar Documents

Publication Publication Date Title
ATE381554T1 (de) Aroylfurane und aroylthiophene, die sich für die behandlung von krebs eignen
CY1107422T1 (el) Φουραζανοβενζιμιδαζoλες
SE0300119D0 (sv) Novel compounds
TW200519088A (en) Aryl or heteroaryl amide compounds
AP1635A (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease.
SE0202133D0 (sv) Novel compounds
SE0104140D0 (sv) Novel Compounds
RS20060129A (en) /1,8/naphthyridin-2-ones and related compounds for the treatment of schizophrenia
MXPA04000677A (es) Tienopirimidindionas y su uso en modulacion de enfermedades autoinmunes.
MXPA02012425A (es) Compuestos nuevos.
CY1109906T1 (el) Παραγωγα c3-kyano εποθιλονης
SE0300480D0 (sv) Novel compounds
SE0302139D0 (sv) Novel compounds
TW200833670A (en) Novel compounds 569
MX2007008308A (es) Derivados de n-(heteroaril)-1h-indol-2-carboxamidas y su utilizacion como ligandos del receptor vaniloide trpv1-.
DE602005022284D1 (de) Substituierte benzimidazole und deren verwendung zur induktion von apoptose
TW200740781A (en) Novel compounds
TW200604197A (en) New compounds
DE602004029355D1 (de) Sulfopyrrolderivate
SE0101038D0 (sv) Novel compounds
ATE485822T1 (de) Phenylaminopyridine und phenylaminopyrazine
SE0300456D0 (sv) Novel compounds
GB0120461D0 (en) Novel compounds
SE0401763D0 (sv) Compounds
SE0303090D0 (sv) Novel compounds

Legal Events

Date Code Title Description
8364 No opposition during term of opposition